// App-Quantinova.ai

458 : Safety and feasibility of an HPV therapeutic vaccine (TA-CIN) in patients with HPV16 associated cervical cancer

Researchers

Presenter

  • Stephanie Gaillard

Principal Investigators

  • Amy Deery

  • Amanda Nickles Fader

  • Warner Huh

  • Margaret Liang

  • Michael Straughn

  • Rebecca Arend

  • T.c. Wu

  • Charles Leath

  • Richard Roden

Medical Centers

  • Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, United States

  • Massachusetts General Hospital, Boston, MA, United States

  • Campus Gasthuisberg, University Hospitals Leuven, Leuven, Belgium

  • Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States

  • Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States

  • Clinica Universidad de Navarra, Madrid, Spain

  • Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

  • UC San Diego Moores Cancer Center, La Jolla, CA, United States

  • University Hospital Universitario Reina Sofia, Cordoba, Spain

  • Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY, United States

  • Istituto Nazionale Tumori - Fondazione “G. Pascale” - Napoli, Naples, Italy

  • Hospital Universitario La Paz, Madrid, Spain

  • Medical University of Innsbruck, Innsbruck, Austria

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gynaecological cancer

Biomarkers

  • N/A

Drug/Treatment

  • Human papilloma virus vaccine

  • Cisplatin

  • Immunol

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved